Prime Medicine Statistics
Share Statistics
Prime Medicine has 131.16M shares outstanding. The number of shares has increased by 9.36% in one year.
| Shares Outstanding | 131.16M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 9.27% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 50.89M |
| Failed to Deliver (FTD) Shares | 6.45K |
| FTD / Avg. Volume | 0.56% |
Short Selling Information
The latest short interest is 16.13M, so 12.3% of the outstanding shares have been sold short.
| Short Interest | 16.13M |
| Short % of Shares Out | 12.3% |
| Short % of Float | 31.7% |
| Short Ratio (days to cover) | 12.98 |
Valuation Ratios
The PE ratio is -4.07 and the forward PE ratio is -3.06.
| PE Ratio | -4.07 |
| Forward PE | -3.06 |
| PS Ratio | 0 |
| Forward PS | 9 |
| PB Ratio | 6.06 |
| P/FCF Ratio | -4.63 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Prime Medicine Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.53, with a Debt / Equity ratio of 0.
| Current Ratio | 2.53 |
| Quick Ratio | 2.53 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.49% and return on capital (ROIC) is -130.21%.
| Return on Equity (ROE) | -1.49% |
| Return on Assets (ROA) | -1.02% |
| Return on Capital (ROIC) | -130.21% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -846.72K |
| Employee Count | 234 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -279.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -61.63% in the last 52 weeks. The beta is 2.09, so Prime Medicine 's price volatility has been higher than the market average.
| Beta | 2.09 |
| 52-Week Price Change | -61.63% |
| 50-Day Moving Average | 3.28 |
| 200-Day Moving Average | 4.67 |
| Relative Strength Index (RSI) | 39.6 |
| Average Volume (20 Days) | 1.15M |
Income Statement
| Revenue | n/a |
| Gross Profit | -147.91M |
| Operating Income | -191.29M |
| Net Income | -198.13M |
| EBITDA | -193.76M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2.18 |
Balance Sheet
The company has 41.57M in cash and 13.63M in debt, giving a net cash position of 27.94M.
| Cash & Cash Equivalents | 41.57M |
| Total Debt | 13.63M |
| Net Cash | 27.94M |
| Retained Earnings | -491.33M |
| Total Assets | 332.78M |
| Working Capital | 208.19M |
Cash Flow
In the last 12 months, operating cash flow was -165.41M and capital expenditures -8.72M, giving a free cash flow of -174.14M.
| Operating Cash Flow | -165.41M |
| Capital Expenditures | -8.72M |
| Free Cash Flow | -174.14M |
| FCF Per Share | -1.91 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
PRME does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -81.04% |
| FCF Yield | -49.36% |
Analyst Forecast
The average price target for PRME is $13.5, which is 401.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $13.5 |
| Price Target Difference | 401.9% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Scores
| Altman Z-Score | -2.1 |
| Piotroski F-Score | 5 |